-
公开(公告)号：US20210169876A1
公开(公告)日：2021-06-10
申请号：US17114379
申请日：2020-12-07
申请人： Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
发明人： Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , James L. Kirkland , Tamar Tchkonia , Yi Zhu
IPC分类号： A61K31/496 , A61P11/00 , A61P9/10 , A61P27/02 , A61K31/428 , A61K31/495 , A61K31/5377 , C12N15/113 , A61P25/28 , A61K47/68 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号：US10517866B2
公开(公告)日：2019-12-31
申请号：US15981696
申请日：2018-05-16
申请人： Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人： Remi-Martin Laberge , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Nathaniel David , Alain Philippe Vasserot , Darren J. Baker , Bennett G. Childs , Jan M. A. van Deursen
IPC分类号： A61P9/10 , A61K31/496 , A61P11/00 , A61P27/02 , A61K31/428 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00 , C12Q1/48
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
23.发明申请公开(公告)号：US20190022090A1
公开(公告)日：2019-01-24
申请号：US16054667
申请日：2018-08-03
申请人： Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人： Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Bennett G. Childs , Jan M.A. van Deursen
IPC分类号： A61K31/496 , A61K9/00 , A61K31/428 , A61K47/36 , C12N5/00 , A61K31/728 , A61K31/4178 , A61K45/06 , A61K31/4375 , A61K31/404 , A61K31/5377 , A61K31/495
CPC分类号： A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , A61P9/10 , A61P11/00 , A61P27/02 , C12N5/0081 , C12N2501/999 , C12N2503/02 , C12Q1/485
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号：US20190000846A1
公开(公告)日：2019-01-03
申请号：US16025238
申请日：2018-07-02
申请人： Mayo Foundation for Medical Education and Research , Buck Institute for Research on Aging , Unity Biotechnology, Inc.
发明人： Jan M.A. van Deursen , Bennett G. Childs , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Nathaniel David , Remi-Martin Laberge , Judith Campisi , Marco Demaria
IPC分类号： A61K31/506 , A61P9/14 , A61K31/40 , A61K31/22
摘要： Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. This invention provides senolytic agents that remove senescent cells that are present in or around atherosclerotic plaques. The agents inhibit or reverse thinning of the fibrous cap on atherosclerotic plaques. This has the effect of stabilizing the plaques, inhibiting rupture and preventing pathological sequelae that manifest as coronary artery disease. Senolytic agents used in this way complement the action of statins and other drugs that cause plaque regression. Thus, senolytic agents and lipid lowering drugs can be used in combination for enhanced therapeutic effect.
-
公开(公告)号：US20180303828A1
公开(公告)日：2018-10-25
申请号：US16007880
申请日：2018-06-13
申请人： Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人： Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jan M.A. van Deursen
IPC分类号： A61K31/496 , A61K31/428 , A61K45/06 , A61K31/495 , A61K31/5377 , A61K9/00 , A61K31/404 , A61K31/4375
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
26.发明申请公开(公告)号：US20180235956A1
公开(公告)日：2018-08-23
申请号：US15955542
申请日：2018-04-17
申请人： Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
发明人： Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jan M.A. van Deursen
IPC分类号： A61K31/496 , A61K45/06 , A61K31/5377 , A61K31/495 , A61K9/00 , A61K31/428 , A61K31/404 , A61K31/4375
CPC分类号： A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , A61P11/00 , C12N5/0081 , C12N2501/999 , C12N2503/02
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号：US20180193458A1
公开(公告)日：2018-07-12
申请号：US15742458
申请日：2016-07-08
申请人： Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人： Jose Alberto Lopez-Dominguez , Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , Darren J. Baker , Bennett G. Childs , James L. Kirkland , Tamar Tchkonia , Jan M.A. van Deursen , Yi Zhu
IPC分类号： A61K45/06 , A61K31/407 , A61K31/428 , A61K31/4375 , A61K31/496 , C07K14/47 , A61P35/00 , A61P9/10
CPC分类号： A61K45/06 , A01K2227/105 , A01K2267/0375 , A61K31/40 , A61K31/4035 , A61K31/407 , A61K31/428 , A61K31/4375 , A61K31/496 , A61K31/635 , A61P9/10 , A61P35/00 , C07K14/4747 , C12N15/113 , C12N2310/14 , C12N2310/531 , A61K2300/00
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
-
28.发明申请公开(公告)号：US20190269675A1
公开(公告)日：2019-09-05
申请号：US16403389
申请日：2019-05-03
申请人： Buck Institute for Research and Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
发明人： Shankar J. Chinta , Judith Campisi , Julie K. Andersen , Remi-Martin Laberge , Nathaniel David , James L. Kirkland , Tamar Tchkonia , Yi Zhu
IPC分类号： A61K31/496 , A61K9/00 , A61P9/10 , A61K47/36 , A61P11/00 , A61P27/02 , C12N5/00 , A61K31/728 , A61K31/4178 , A61K45/06 , A61K31/4375 , A61K31/404 , A61K31/5377 , A61K31/495 , A61K31/428
摘要： This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease.
-
29.发明申请公开(公告)号：US20170216286A1
公开(公告)日：2017-08-03
申请号：US15113723
申请日：2015-01-28
发明人： James L. Kirkland , Tamar Tchkonia , Yi Zhu , Allyson K. Palmer , Nathan K. LeBrasseur , Jordan D. Miller
IPC分类号： A61K31/506 , A61K31/352
CPC分类号： A61K31/506 , A61K31/352 , A61K31/353 , A61K31/665 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflammatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder.
-
30.发明申请公开(公告)号：US20200316066A1
公开(公告)日：2020-10-08
申请号：US16865179
申请日：2020-05-01
发明人： James L. Kirkland , Tamar Tchkonia , Yi Zhu , Allyson K. Palmer , Nathan K. LeBrasseur , Jordan D. Miller
IPC分类号： A61K31/506 , A61K31/352 , A61K31/7048 , A61K45/06 , A61K31/353 , A61K31/665
摘要： Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflanunatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder.
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.067 秒)
